Core Insights - Teva Pharmaceuticals presented data showing that patients using AUSTEDO XR reported improved social and emotional well-being due to reduced movement symptoms associated with tardive dyskinesia (TD) [1][3][9] - The survey highlighted high patient satisfaction with AUSTEDO XR, with over 96% of participants finding it easy to take and 96% expressing interest in continuing treatment [3][9][10] Group 1: Patient Experience and Survey Results - The noninterventional survey included 209 participants with TD, revealing that over 94% reported improvement in movement symptoms after treatment with AUSTEDO XR [2][9] - More than 77% of patients agreed that the reduction in movements led to greater comfort in social settings and improved emotional well-being [10] - The survey indicated that 91% of patients with prior valbenazine use and 89% of de novo patients reported overall satisfaction with AUSTEDO XR [10] Group 2: Product Information - AUSTEDO XR is the first vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for treating TD and chorea associated with Huntington's disease [6][7] - AUSTEDO XR is a once-daily formulation, enhancing patient compliance and convenience [6] Group 3: Company Commitment - Teva emphasizes its responsibility to understand the lived experiences of patients with TD and aims to innovate treatments that restore freedom and quality of life [2][23]

Core Insights - Neurocrine Biosciences presented new analyses from a Phase 4 randomized withdrawal study showing that patients with tardive dyskinesia who continued treatment with INGREZZA® (valbenazine) capsules reported improvements in functional and health-related quality of life measures [1][2] - The findings were presented at the 2025 ISPOR Conference, highlighting the clinically meaningful improvements in patients' quality of life due to INGREZZA treatment [1][2] Study Details - The analyses were based on data from 127 patients in a Phase 4, double-blind, placebo-controlled study, where patients received up to 80 mg of INGREZZA for eight weeks before being randomized to continue treatment or receive a placebo for an additional eight weeks [2][3] - Significant improvements were observed in health-related quality of life (HRQoL) measures, including mobility, self-care, usual activities, and pain/discomfort, with placebo-adjusted differences noted in anxiety/depression and mobility [3][4] Health-Related Quality of Life Improvements - Patients receiving INGREZZA for eight weeks showed improvements in HRQoL dimensions, with changes from baseline reported as follows: mobility (-0.27), self-care (-0.28), usual activities (-0.36), and pain/discomfort (-0.34) [3] - Continued treatment for an additional eight weeks resulted in further improvements, including a placebo-adjusted difference in mobility of -0.34 and anxiety/depression of -0.38 compared to the placebo group [3] Functional Impairment Improvements - In the open-label portion of the study, patients reported significant improvements in work/school (-1.37), social life (-1.65), family/home life (-1.30), and total Sheehan Disability Scale (SDS) score (-4.28) after eight weeks of treatment [4] - Continued treatment for an additional eight weeks led to further improvements in social life (-0.95) and family/home life (-0.89) compared to those receiving placebo [4] About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease [12][13] - The drug is designed to inhibit dopamine release, potentially reducing uncontrollable movements associated with these conditions [13][14]

Company Overview - Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [21] - The company has a diverse portfolio that includes FDA-approved treatments for tardive dyskinesia (TD) and other conditions, along with a robust pipeline of compounds in clinical development [21] Campaign Launch - The company launched the "ConnectING with Carnie™" multimedia awareness campaign in partnership with Carnie Wilson to raise awareness about tardive dyskinesia [1][5] - The campaign aims to combat stigma, promote diagnosis, and empower patients to seek treatment options, including INGREZZA® (valbenazine) capsules [5] Tardive Dyskinesia (TD) Awareness - Tardive dyskinesia is characterized by uncontrolled, abnormal movements and is associated with the use of certain antipsychotic medications [6][7] - It is estimated that at least 800,000 adults in the U.S. are affected by TD [7] INGREZZA® (valbenazine) Capsules - INGREZZA is an FDA-approved treatment for adults with tardive dyskinesia and is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor [8][9] - The medication is available in 40 mg, 60 mg, and 80 mg capsules and can be taken once daily without the need for titration [10] Campaign Goals - The ultimate goal of the "ConnectING with Carnie" campaign is to encourage individuals living with TD to seek the help they deserve and to reduce stigma surrounding the condition [2][4] - The campaign will feature personal stories and resources for those affected by TD, aiming to foster open discussions about symptoms and treatment options [3][4]

Core Viewpoint - Evoke Pharma, Inc. announced the acceptance of a new abstract for presentation at Digestive Disease Week 2025, focusing on the incidence of tardive dyskinesia in patients treated with metoclopramide [1][3] Company Overview - Evoke Pharma is a specialty pharmaceutical company that develops treatments for gastrointestinal disorders, particularly known for GIMOTI, a nasal spray formulation of metoclopramide for diabetic gastroparesis [6][7] - GIMOTI is the only FDA-approved treatment for diabetic gastroparesis, addressing a significant need in the market [3][7] Research and Findings - The upcoming presentation will compare the incidence rates of tardive dyskinesia in patients receiving continuous versus intermittent oral metoclopramide treatment, utilizing real-world data from over 100 million U.S. patients [2][4] - The research aims to clarify the long-term safety profile of metoclopramide, particularly regarding tardive dyskinesia, to support informed prescribing decisions [3][4] Event Details - The abstract titled "Comparison of the Incidence of Tardive Dyskinesia in Patients Receiving Continuous vs Intermittent Oral Metoclopramide" will be presented by Pierantonio Russo, MD, during a session on gastroparesis and small intestinal dysmotility on May 5, 2025 [4] - The abstract will be accessible to attendees via the DDW ePosters site and mobile app starting May 4, 2025 [4] Industry Context - Digestive Disease Week (DDW) is a major international event for professionals in gastroenterology, showcasing advancements in GI research and medicine [8]